ME00233B - Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere - Google Patents

Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere

Info

Publication number
ME00233B
ME00233B MEP-2008-341A MEP2008341A ME00233B ME 00233 B ME00233 B ME 00233B ME P2008341 A MEP2008341 A ME P2008341A ME 00233 B ME00233 B ME 00233B
Authority
ME
Montenegro
Prior art keywords
release
treatment agent
ionic
relates
present
Prior art date
Application number
MEP-2008-341A
Other languages
English (en)
French (fr)
Inventor
Howard L Levine
William J Bologna
Original Assignee
Columbia Laboratories Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/278,912 external-priority patent/US20030114394A1/en
Application filed by Columbia Laboratories Bermuda Ltd filed Critical Columbia Laboratories Bermuda Ltd
Publication of ME00233B publication Critical patent/ME00233B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ovaj pronalazak se odnosi na sistem oslobađanja farmaceutskog preparata koji se oslanja na jonsku interakciju koja kontroliše i olakšava oslobađanje agensa za tretiranje. Određenije, ovaj pronalazak se odnosi na sistem za produženo, kontrolisano oslobađanje, koji sadrži jonski agens za tretiranje i jonski polimer, gde je taj polimer dovoljno jonizovan da oslobađa agens za tretiranje na kontrolisan način, tokom produženog perioda vremena, a taj preparat ne sadrži emulzioni sistem za ordiniranje agensa za tretiranje. Ovaj pronalazak se odnosi na sistem oslob a đ anja farmaceutskog preparata koji se oslanja na jonsku interakciju koja kontrol i š e i ola k š ava oslob a đ anje agensa za tretiranje. Odr e đ enije, ovaj pronalazak se odnosi na sistem za prod u ž eno, kontrolisano oslob a đ anje, koji sad r ž i jonski agens za tretiranje i jonski polimer, gde je taj polimer dovoljno jonizovan da oslob a đ a agens za tretiranje na kontrolisan n a č in, tokom prod u ž enog perioda vremena, a taj preparat ne sad r ž i emulzioni sistem za ordiniranje agensa za tretiranje.    
MEP-2008-341A 2002-10-24 2003-04-25 Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere ME00233B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/278,912 US20030114394A1 (en) 2001-10-29 2002-10-24 Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US43850103P 2003-01-08 2003-01-08
PCT/EP2003/004316 WO2004037229A1 (en) 2002-10-24 2003-04-25 Extended, controlled release pharmaceutical compositions comprising charged polymers

Publications (1)

Publication Number Publication Date
ME00233B true ME00233B (me) 2011-05-10

Family

ID=32179474

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-341/08A MEP34108A (en) 2002-10-24 2003-04-25 Extended, controlled release pharmaceutical compositions comprising charged polymers
MEP-2008-341A ME00233B (me) 2002-10-24 2003-04-25 Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-341/08A MEP34108A (en) 2002-10-24 2003-04-25 Extended, controlled release pharmaceutical compositions comprising charged polymers

Country Status (23)

Country Link
EP (1) EP1556015B1 (me)
JP (1) JP5204374B2 (me)
KR (1) KR20050083802A (me)
CN (2) CN101327326A (me)
AR (1) AR039464A1 (me)
AU (1) AU2003233066B2 (me)
BR (1) BR0315576A (me)
CA (1) CA2503383C (me)
CO (1) CO5700711A2 (me)
ES (1) ES2618300T3 (me)
HR (1) HRP20050448A2 (me)
MA (1) MA27493A1 (me)
ME (2) MEP34108A (me)
MX (1) MXPA05004330A (me)
NO (1) NO20052480L (me)
NZ (1) NZ539512A (me)
PE (2) PE20081613A1 (me)
PL (1) PL376537A1 (me)
RS (1) RS20050321A (me)
RU (2) RU2366410C2 (me)
TW (1) TW200406223A (me)
WO (1) WO2004037229A1 (me)
ZA (1) ZA200503133B (me)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006244214A1 (en) * 2005-05-10 2006-11-16 Novartis Ag Modified release famciclovir pharmaceutical compositions
WO2017130208A1 (en) * 2016-01-29 2017-08-03 Faheem Hyder Pottoo Triple drug combination for treatment of status epilepticus and/or partial seizures and/or partial seizures with associated neurological disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163696B1 (en) * 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
UA74168C2 (uk) * 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу

Also Published As

Publication number Publication date
PE20081613A1 (es) 2008-11-15
RU2366410C2 (ru) 2009-09-10
CO5700711A2 (es) 2006-11-30
AU2003233066B2 (en) 2009-11-19
EP1556015A1 (en) 2005-07-27
CN1703205B (zh) 2010-12-01
JP2006506453A (ja) 2006-02-23
MA27493A1 (fr) 2005-08-01
AU2003233066A1 (en) 2004-05-13
ZA200503133B (en) 2006-12-27
MEP34108A (en) 2011-02-10
MXPA05004330A (es) 2005-08-02
TW200406223A (en) 2004-05-01
EP1556015B1 (en) 2017-02-22
NO20052480D0 (no) 2005-05-23
KR20050083802A (ko) 2005-08-26
CA2503383C (en) 2013-03-12
AR039464A1 (es) 2005-02-23
CN1703205A (zh) 2005-11-30
WO2004037229A1 (en) 2004-05-06
PL376537A1 (pl) 2006-01-09
ES2618300T3 (es) 2017-06-21
CA2503383A1 (en) 2004-05-06
RU2005115574A (ru) 2005-10-27
CN101327326A (zh) 2008-12-24
PE20040323A1 (es) 2004-06-10
NZ539512A (en) 2009-03-31
NO20052480L (no) 2005-07-25
HRP20050448A2 (en) 2005-12-31
RU2009112072A (ru) 2010-10-10
JP5204374B2 (ja) 2013-06-05
RS20050321A (en) 2007-08-03
BR0315576A (pt) 2005-08-30

Similar Documents

Publication Publication Date Title
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
PL1931316T5 (pl) Kompozycje farmaceutyczne o kontrolowanym uwalnianiu dla leków labilnych kwasowo
BRPI0509366B8 (pt) composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica
FI3925607T3 (fi) Farmaseuttisia koostumuksia kystisen fibroosin transmembraanisen konduktanssinsäätäjän välittämien tautien hoitamiseksi
ME00199B (me) Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
RS52922B (en) PREPARATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR USES
EA200701575A1 (ru) Формуляция леветирацетама длительного высвобождения
EA200970342A1 (ru) Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
RU2008142524A (ru) Устойчивая пероральная фармацевтическая композиция, содержащая агонисты рецепторов тиреодных гормонов
TW200833376A (en) Sustained-release composition and method for producing the same
DK0885014T3 (da) Farmaceutiske præparater indeholdende bufrede orthoesterpolymerer
JP5697668B2 (ja) 口腔内崩壊錠剤
ME00233B (me) Farmaceutske kompozicije sa produženim, kontrolisanim oslobađanjem koje sadrže naelektrisane polimere
MX339136B (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
DE60313898D1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
CA2648538A1 (en) Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles
HRP20090225T1 (en) Pharmaceutical compositions based on nk2 antagonists for pediatric use
RU2014144502A (ru) Комбинированный препарат лерканидипина гидрохлорида и лозартана калия и способ его получения
AU2003256882A8 (en) Methods of drug delivery using sulphated chitinous polymers
DK1699468T3 (da) Farmaceutisk sammensætning, der omfatter et zink-hyaluronatkompleks, til behandling af dissemineret skelrose
EA200601283A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер
ATE442838T1 (de) Verfahren zur herstellung einer festen pharmazeutischen zusammensetzung